Bradley K Ackerson, Katia J Bruxvoort, Lei Qian, Lina S Sy, Sijia Qiu, Julia E Tubert, Gina S Lee, Jennifer H Ku, Ana Florea, Yi Luo, Radha Bathala, Julie Stern, Soon K Choi, Harpreet S Takhar, Michael Aragones, Morgan A Marks, Evan J Anderson, Cindy Ke Zhou, Tianyu Sun, Carla A Talarico, Hung Fu Tseng
Emerging SARS-CoV-2 sublineages continue to cause serious COVID-19 disease, but most individuals have not received any COVID-19 vaccine for >1 year. Assessment of long-term effectiveness of bivalent COVID-19 vaccines against circulating sublineages is important to inform the potential need for vaccination with updated vaccines. In this test-negative study at Kaiser Permanente Southern California, sequencing-confirmed BA.4/BA.5- or XBB-related SARS-CoV-2-positive cases (September 1, 2022 to June 30, 2023), were matched 1:3 to SARS-CoV-2-negative controls...
December 31, 2024: Human Vaccines & Immunotherapeutics